CriticalAntifungal, triazole×HMG-CoA reductase inhibitor (statin)
Updated · Methodology
Mechanism
Strong CYP3A4 inhibitor – lovastatin rises 20+ fold. FDA contraindication.
Symptoms
Myalgia, weakness, dark urine, rising CK within 5-10 days.
Management
Combination contraindicated.
Check the full regimen, not just this pair
Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.
Summary of a multi-drug list →
Medicine list: everything you take in one place →
Sources
- FDA: Lovastatin tablet (Bluepoint Laboratories) – Prescribing Information – CYP3A4 contraindications (2014)– FDA Mevacor label, Contraindications §4; DailyMed setid 7b86160d-74a9-4774-b5b3-5641e686991f
- FDA: Sporanox (itraconazole) prescribing information – CYP3A4 inhibition contraindications (2020)– FDA Sporanox label, Contraindications §4 and Drug Interactions §7; DailyMed setid a4d555fa-787c-40fb-bb7d-b0d4f7318fd0
- FDA: Lovastatin tablets – Prescribing Information (2014)
- AEMPS: Ficha técnica: Lovastatina (nº registro 64438), sección 4.3 (2023)– AEMPS, CIMA, nº registro 64438, revisión 07/2023, sección 4.3